Use of Modafinil in the Treatment of Tinnitus

University of Arkansas

Status and phase

Terminated

Phase 1

Conditions

Tinnitus

Treatments

Drug: Modafinil

Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT00591019

# 65171

Details and patient eligibility

About

A study on the effects of the FDA approved drug Modafinil upon attention problems associated with tinnitus. This is considered to be a safe drug with few side effects. Each subject will be asked to participate in 3 sessions each lasting approximately 1 hour in which cognitive testing and recordings will be taken. The study involves each subject taking a 2- week supply of Modafinil and a 2- week supply of placebo. We hypothesize inattention related to thalamocortical dysrhythmia found in tinnitus can be reduced by Modafinil thus improving vigilance.

Full description

Modafinil, a drug primarily used in the treatment for narcolepsy, is also being using in treating attention problems found in Attention Deficit Hyperactive Disorder (ADHD). This study will investigate the efficacy of Modafinil upon attention deficits found in tinnitus patients by assessing pre-attentional and attentional processes (e.g., the amplitude of auditory evoked responses and simple reaction time).

Enrollment

7 patients

Sex

All

Ages

20 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

The diagnosis of tinnitus should be established by subject through exam and history performed by study physician in Ear, Nose and Throat (ENT) clinic.
Subjects will be age 20 or older.
Subjects should have tinnitus symptoms severe enough to seek medical attention.
Subjects will have been seen in the Hearing and Balance Center at University of Arkansas for Medical Sciences (UAMS).
Subjects will have had an audiogram.
Signed informed consent.
Women of childbearing potential must have a negative pregnancy test at screening and before being prescribed the study drug.
Peripheral neuropathy.
Hematologic (minimal values) at screening Absolute neutrophil count > 1,500 mm^3 Hemoglobin > 8.0 g/dl Platelet count > 100,000 mm^3

Exclusion criteria

Disease-Specific Concerns

Subjects who have locally advanced breast cancer with skin ulceration will be excluded from this study due to the risk of worsening ulcers and healing difficulties
Stage IV breast cancer
Inflammatory breast cancer

General Medical Concerns

Subjects with Echo Cardiogram performance status 2, 3, and 4 are not eligible for this study
Allergy to any component of the treatment regimen
Women who are breast feeding
Pregnancy or refusal to use effective contraception while participating in this study
Inability to comply with study and/or follow-up procedures
Subjects with secondary malignancy other than superficial skin cancer (squamous cell carcinoma and basal cell carcinoma of the skin) should be excluded

Bevacizumab-Specific Concerns

Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
Blood pressure of > 150/100 mmHg. Essential hypertension well controlled with anti hypertensive is not an exclusion criterion
Unstable angina
New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix D)
History of myocardial infarction within 6 months
History of stroke within 6 months
Clinically significant peripheral vascular disease
Evidence of bleeding diathesis or coagulopathy
Presence of central nervous system or brain metastases
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
Pregnant (positive pregnancy test) or lactating
Urine protein: creatinine ratio >1.0 at screening
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
Serious, non-healing wound, ulcer, or bone fracture